Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial | Nature Medicine
Seyda Gunduz on X: "#PARADIGM trial First-line Panitumab is superior to bevacizumab in the left-sided RAS wild metastatic colon cancer #ASCO22 https://t.co/6XLAWIK1c2" / X
Management of metastatic colorectal cancer | PPT
New options being investigated in advanced or metastatic colorectal cancer
Frontiers | Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements
Frontiers | Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer
Seyda Gunduz on X: "#PARADIGM trial First-line Panitumab is superior to bevacizumab in the left-sided RAS wild metastatic colon cancer #ASCO22 https://t.co/6XLAWIK1c2" / X
Comparison of current versus the evolving ctDNA-guided adjuvant therapy... | Download Scientific Diagram
Comment: PARADIGM trial results for RAS wild-type metastatic colorectal cancer on Vimeo
Metastatic Colon and Rectal Cancer Updates, ASCO 2022
Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management - ScienceDirect
IJMS | Free Full-Text | Total Neoadjuvant Treatment for Locally Advanced Rectal Cancer Patients: Where Do We Stand?
Current Oncology | Free Full-Text | Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer
Yüksel Ürün on X: "PARADIGM trial: 1st-L treatment in patients with RAS wild-type metastatic colorectal cancer 🔸PAN + mFOLFOX6 >> BEV + mFOLFOX6, HR 0.82 for OS (in left-sided tumors) 🔸No difference
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer | Nature Medicine
PARADIGM Study Design & Clinical Data | Vectibix® (panitumumab)
ASCO GI 2023 Biomarker Study of The Phase III PARADIGM Trial: Negative Hyperselection of Patients With RAS WT mCRC for Panitumumab | VuMedi
Study design of the FIRE-4 (AIO KRK-0114) trial. | Download Scientific Diagram
RAS野生型の切除不能進行再発大腸癌の一次治療においてPanitumumab＋mFOLFOX6療法とBevacizumab＋mFOLFOX6療法を比較した無作為化第III相試験（ PARADIGM試験） | GI cancer-netR 海外学会速報レポート
PARADIGM Study Design & Clinical Data | Vectibix® (panitumumab)
Personalized Care in Colorectal Cancer: Tailoring Treatment and Healthcare Delivery - Personalized Medicine in Oncology
World-first confirmation of standard treatment for RAS wild-type colorectal cancer －Paper published in JAMA－ | National Cancer Center Japan
Therapeutic landscape and future direction of metastatic colorectal cancer | Nature Reviews Gastroenterology & Hepatology
Neoadjuvant immunotherapy in dMMR colon cancer
Comprehensive review of targeted therapy for colorectal cancer | Signal Transduction and Targeted Therapy
Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy‐naïve Patients With RAS (KRAS/NRAS) Wild‐type, Metastatic Colorectal Cancer | Semantic Scholar
ASCO Guideline Highlights Newest Breakthroughs in the Treatment of Metastatic Colorectal Cancer - The ASCO Post
